Hadassah

FDA Approves US Clinical Trials to Treat ALS with Israel Stem Cell Technology

Wednesday, Apr 30 2014

The United States Food and Drug Administration (FDA) has approved the start of multi-center Phase II clinical trials in the United States to treat amyotrophic lateral sclerosis (ALS) with adult stem cell technology first introduced by the Hadassah Medical Organization’s Prof. Dimitrios Karussis, Senior Neurologist and head of Hadassah’s Multiple Sclerosis Center.

The treatment, developed by Israel’s BrainStorm Cell Therapeutics, involves injecting autologous stem cells (coming from the patients themselves) into the spinal fluid. Earlier clinical trials at Hadassah have shown that the treatment was both well tolerated and safe. “Ten of the 15 patients in the Hadassah trials responded or stabilized,” reports Prof. Karussis, “and the disease was halted, with their breathing improved. About three of them even showed that the disease had receded, with them improving dramatically.” He notes, however, that the treatment is not a permanent cure. The injection “probably has to be repeated after several months.”

Trials will begin at Massachusetts General Hospital in Boston and the University of Massachusetts Memorial Hospital in Worcester and later be initiated at the Mayo Clinic in Minnesota.
Read more in The Jerusalem Post

Related Stories

alt_text

Wednesday, Jul 8 2020

Cancer Trailblazers at Hadassah Prioritize a Spirit of Innovation

For many decades, chemotherapy and radiation were the chief therapies to treat cancer. Today, at major medical centers like the Hadassah Medical Organization, cancer specialists...

READ MORE ›
alt_text

Monday, Jul 6 2020

The Altruism of Donating an Organ During the COVID-19 Pandemic

During the COVID-19 pandemic, altruistic gestures have assumed special meaning as people continue to donate organs to help others live...

READ MORE ›
alt_text

Monday, Jul 6 2020

COVID-19 Pandemic Creates Confusion, Contradictions, and Changeability

“There is simultaneously a profusion of information, but a dearth of answers.” That’s how Barbara Sofer, the Israel director of public relations at Hadassah’s office in Israel...

READ MORE ›
alt_text

Monday, Jul 6 2020

Evolution, Findings, and Outlook—Hadassah Director Reflects on COVID-19

Many people around the world watched with admiration as Israel efficaciously contained COVID-19 at the start of the pandemic with a strict lockdown...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More